Avenacy intros generic Alkeran
Avenacy, a specialty pharmaceutical company focused on supplying injectable medications, is offering Melphalan Hydrochloride, which is the generic for Apotex’s Alkeran.
Melphalan Hydrochloride for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
Avenacy’s Melphalan Hydrochloride for Injection is available in a kit containing a 50 mg vial of lyophilized active ingredient and a 10 ml vial of sterile diluent for admixture. This product is formulated to allow storage at room temperature, enabling wider use in medical settings through greater transportability and ease of access. In line with Avenacy’s mission to champion patient safety and streamline patient care, Melphalan Hydrochloride for Injection will feature the company’s highly differentiated packaging and labeling to support accurate medication selection.
“Avenacy’s first product to market comes less than three months after our launch as a new specialty pharmaceutical company and is a testament to our seasoned team and strong relationships with partners. We are building on our momentum as we enter 2024 and plan to introduce several additional new products in the coming months,” said Jeff Yordon, co-founder and CEO of Avenacy. “Melphalan Hydrochloride for Injection will feature our proprietary product packaging and labeling, supporting our commitment to championing reliability, safety, and convenience for our customers. As Avenacy continues to grow, I look forward to working with our global partners to deliver more critical injectable medications to hospitals and healthcare providers.”
[Read more: Challenges continue, but generics companies see a bright future with biosimilars]
Avenacy is initiating commercial operations throughout the United States and will begin shipping Melphalan Hydrochloride for Injection to wholesale partners this week. The company is supported by a global network of development and manufacturing partners, including Arthur Group (as the Abbreviated New Drug Application holder) and Qilu Pharmaceutical (as the FDA-approved cGMP-certified contract manufacturing organization).
Melphalan Hydrochloride for Injection had a market value of approximately $25 million for the 12 months ending in June 2023, per IQVIA.
[Read more: AAM report: Generic, biosimilar drugs generate $408B in savings]